These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 27593867

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
    Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P.
    Diabetes Technol Ther; 2004 Feb; 6(1):1-8. PubMed ID: 15000763
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S, Chen M, Chen W, Lin K, Mu P, Zhu B, Xu W, Wang M, Weng J, Zeng L.
    J Diabetes Res; 2018 Feb; 2018():2791584. PubMed ID: 30420969
    [Abstract] [Full Text] [Related]

  • 8. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I.
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [Abstract] [Full Text] [Related]

  • 9. Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics.
    Ji L, Zhang P, Weng J, Lu J, Guo X, Jia W, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Li X, Zhu D, Li Y, Wu Y, Garg SK.
    Diabetes Technol Ther; 2015 Oct; 17(10):735-44. PubMed ID: 26171728
    [Abstract] [Full Text] [Related]

  • 10. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents.
    Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E.
    Diabetes Care; 2009 Jun; 32(6):1058-62. PubMed ID: 19244086
    [Abstract] [Full Text] [Related]

  • 11. Medication adherence to oral hypoglycemic agents among type II diabetic patients and their clinical outcomes with special reference to fasting blood glucose and glycosylated hemoglobin levels.
    Shrestha SS, Shakya R, Karmacharya BM, Thapa P.
    Kathmandu Univ Med J (KUMJ); 2013 Jun; 11(43):226-32. PubMed ID: 24442171
    [Abstract] [Full Text] [Related]

  • 12. Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus.
    Jang SY, Jang J, Yang DH, Cho HJ, Lim S, Jeon ES, Lee SE, Kim JJ, Kang SM, Baek SH, Cho MC, Choi DJ, Yoo BS, Kim KH, Park SK, Lee HY.
    Cardiovasc Diabetol; 2021 Sep 08; 20(1):180. PubMed ID: 34496864
    [Abstract] [Full Text] [Related]

  • 13. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes.
    Tamemoto H, Ikoma A, Saitoh T, Ishikawa SE, Kawakami M.
    Diabetes Technol Ther; 2007 Jun 08; 9(3):246-53. PubMed ID: 17561795
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.
    Diabetes Care; 1998 Apr 08; 21(4):574-9. PubMed ID: 9571345
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea.
    Kim SG, Kim NH, Ku BJ, Shon HS, Kim DM, Park TS, Kim YS, Kim IJ, Choi DS.
    J Diabetes Investig; 2017 May 08; 8(3):346-353. PubMed ID: 27712034
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bedtime intermediate-acting insulin in the treatment of secondary failure to oral hypoglycemic agents.
    Chuang LM, Lu C, Su RJ, Wu HP, Tai TY, Lin BJ.
    J Formos Med Assoc; 1992 Feb 08; 91(2):185-9. PubMed ID: 1364216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.